title: CDX2: Linking Cell and Patient Fates in Colon Cancer.
abstract: Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.
authors: Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA.
authors: Eric R
authors: ER
authors: Fearon
authors: Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA; Department of Colorectal Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA. Electronic address: huange2@ccf.org.
authors: Emina H
authors: EH
authors: Huang
mesh_terms: D000071616:CDX2 Transcription Factor; D019070:Cell Lineage; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D018398:Homeodomain Proteins / Q000378:metabolism; D006801:Humans; D014411:Neoplastic Stem Cells / Q000473:pathology; D015534:Trans-Activators / Q000378:metabolism
chemical_list: D000071616:CDX2 Transcription Factor; D018398:Homeodomain Proteins; D015534:Trans-Activators